[go: up one dir, main page]

AR023398A1 - Terapia para melanomas - Google Patents

Terapia para melanomas

Info

Publication number
AR023398A1
AR023398A1 ARP000101574A ARP000101574A AR023398A1 AR 023398 A1 AR023398 A1 AR 023398A1 AR P000101574 A ARP000101574 A AR P000101574A AR P000101574 A ARP000101574 A AR P000101574A AR 023398 A1 AR023398 A1 AR 023398A1
Authority
AR
Argentina
Prior art keywords
therapy
melanomas
treatment
well
alpha
Prior art date
Application number
ARP000101574A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR023398A1 publication Critical patent/AR023398A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen métodos para tratar pacientes nuevos al tratamiento, así como también pacientes con experiencia en el tratamiento, que tienen melanoma, paraincrementar el tiempo de supervivencia libre de progresion que involucra la administracion de unacantidad terapéuticamente eficaz de interferon-alfa pegilado,por ejemplo, interferon alfa-2b pegilado, así como también terapia coadyuvante para cirugía definitiva.
ARP000101574A 1999-04-08 2000-04-06 Terapia para melanomas AR023398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28836699A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
AR023398A1 true AR023398A1 (es) 2002-09-04

Family

ID=23106795

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101574A AR023398A1 (es) 1999-04-08 2000-04-06 Terapia para melanomas

Country Status (22)

Country Link
EP (3) EP2025344B1 (es)
JP (1) JP2000319195A (es)
CN (1) CN1390132A (es)
AR (1) AR023398A1 (es)
AT (3) ATE419001T1 (es)
AU (1) AU771569B2 (es)
BR (1) BR0009646A (es)
CA (1) CA2303992A1 (es)
CO (1) CO5170404A1 (es)
CY (1) CY1108922T1 (es)
DE (3) DE60045591D1 (es)
DK (2) DK1043026T3 (es)
ES (2) ES2319776T3 (es)
HK (2) HK1032349A1 (es)
HU (1) HU230057B1 (es)
MY (1) MY126763A (es)
NO (1) NO328111B1 (es)
PE (1) PE20010027A1 (es)
PT (2) PT1043026E (es)
TW (1) TWI292320B (es)
WO (1) WO2000061175A2 (es)
ZA (1) ZA200108173B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2699965T3 (es) 2011-03-10 2019-02-13 Provectus Pharmatech Inc Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates

Also Published As

Publication number Publication date
ATE296639T1 (de) 2005-06-15
DE60041290D1 (de) 2009-02-12
PT1043026E (pt) 2005-09-30
JP2000319195A (ja) 2000-11-21
DK1043026T3 (da) 2005-07-04
MY126763A (en) 2006-10-31
HK1075416A1 (en) 2005-12-16
ZA200108173B (en) 2003-01-06
EP1535622B1 (en) 2008-12-31
EP2025344A1 (en) 2009-02-18
DK1535622T3 (da) 2009-04-20
HUP0200775A3 (en) 2002-09-30
TWI292320B (en) 2008-01-11
PE20010027A1 (es) 2001-02-05
CA2303992A1 (en) 2000-10-08
EP1043026A2 (en) 2000-10-11
ATE496631T1 (de) 2011-02-15
HK1032349A1 (en) 2001-07-20
AU4204600A (en) 2000-11-14
WO2000061175A2 (en) 2000-10-19
AU771569B2 (en) 2004-03-25
NO20014852D0 (no) 2001-10-05
DE60045591D1 (de) 2011-03-10
CY1108922T1 (el) 2014-07-02
HUP0200775A2 (en) 2002-08-28
EP1043026B1 (en) 2005-06-01
DE60020444T2 (de) 2006-05-04
ES2319776T3 (es) 2009-05-12
PT1535622E (pt) 2009-03-19
CN1390132A (zh) 2003-01-08
EP1535622A1 (en) 2005-06-01
NO20014852L (no) 2001-12-06
NO328111B1 (no) 2009-12-07
ATE419001T1 (de) 2009-01-15
ES2239954T3 (es) 2005-10-16
BR0009646A (pt) 2002-02-05
EP1043026A3 (en) 2000-12-20
HU230057B1 (hu) 2015-06-29
WO2000061175A3 (en) 2001-02-01
DE60020444D1 (de) 2005-07-07
CO5170404A1 (es) 2002-06-27
EP2025344B1 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
CO4940414A1 (es) Terapia de interferones polietilenglicol modificados
PT1173178E (pt) Composicao compreendendo apomorfina e sildenafil e utilizacao da mesma para o tratamento da disfuncao erectil
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
BR0014912A (pt) Tratamento de distúrbios do sono usando desloratadina
ES2267706T3 (es) Agentes como la nicotinamida o cardr para el tratamiento de trastornos de la piel.
BR0309837A (pt) Forma de administração trans-epicutânea para tratamento da sìndrome das pernas inquietas
HUP0002755A2 (hu) Eljárások szklerózis multiplexben szenvedő betegek kezelésére konszenzus interferonnal
NO20072543L (no) Anti-cancer-behandling
BR0115162A (pt) Tratamentos antitumorais eficazes
SI1680128T1 (sl) Mio-inozitol heksafosfat za topično uporabo
BRPI0418157A (pt) terapêutica de tumores alogênicos
JP2003528919A5 (es)
BR0107960A (pt) Tratamento de condições alérgicas e inflamatórias
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
DE60204694D1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
AR023398A1 (es) Terapia para melanomas
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
CO5160259A1 (es) Interferon alfa pegilado en la terapia contra el hiv
ECSP003419A (es) Terapia para melanomas
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
AR025711A1 (es) El uso de la desloratadina para la preparacion de un medicamento para tratar y prevenir estados alergicos e inflamatorios
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
BR0009642A (pt) Terapia de leucemia mielocìtica crÈnica
ECSP003373A (es) Terapia contra el hiv

Legal Events

Date Code Title Description
FB Suspension of granting procedure